Health

EMA pushes COVID-19 vaccine decision forward after German pressure

EMA pushes COVID-19 vaccine decision forward after German pressure

Health

The EU drug regulator has reportedly pushed forward its ruling on the COVID-19 vaccine developed by Pfizer/BioNTech as Germany has made itself heard that it expects the vaccine to get an approval before Christmas.

As per credible sources, the growing backlash from the EU countries has urged the Amsterdam-based European Medicines Agency (EMA) to hold their meeting regarding the authorization of the shot on 21st December instead of the initial 29th December. Commenting on the matter, Jens Spahn, Health Minister for Germany has stated that the body risked losing the trust of EU citizens if it failed to take fast action. Spahn further stated that the

Cats recover from COVID-19 faster than humans; scientists seek reason

Cats recover from COVID-19 faster than humans; scientists seek reason

Health

Scientists at Latvia University of Life Sciences and Technologies (LLU) have taken keen interest in studying the progression of coronavirus in cats, after it was discovered that not a single cat in Latvia has tested positive despite many possessing antibodies. For the record, cats are the most popular pet in Latvia, which has the second highest percentage of cat ownership per household per capita across Europe.

Reportedly, felines, from domestic cats to big cats like lions, can catch COVID-19, however, they seem to recover at a very fast rate as compared to humans. Subsequently, not a single cat in Latvia has tested positive for the virus. However, many have been

Uber asks U.S. senates to allow drivers early access to COVID-19 doses

Uber asks U.S. senates to allow drivers early access to COVID-19 doses

Health

Uber Technologies Inc., an American ridesharing company, has reportedly sent letters to various U.S. state governors requesting them to reclassify its food delivery and ride-hail drivers as essential workers and get early access to the COVID-19 vaccine.

Sources with knowledge of the matter stated that the company will also send a letter to the President of United States Joe Biden.

The recent development comes after Uber had sent similar requests to U.S. Centers for Disease Control and Prevention. Uber reportedly claimed that each of the 1.5 million U.S. drivers have made at least three trips since the outbreak of COVID-19 in March.

Hospitalizations due to COVID-19 hit another record high in the U.S.

Hospitalizations due to COVID-19 hit another record high in the U.S.

Health

The U.S. has reportedly recorded 101,487 COVID-19 hospitalizations last Sunday, as reported by the Covid Tracking Project. Apparently, these hospitalizations have exerted immense pressure on the country’s already burdened hospitals and health care workers.

Commenting on the matter, Dr. Leana Wen, CNN medical analyst and former health commissioner of Baltimore City has stated that the hospitals across the nation are already on the verge of becoming overwhelmed due to which there are possibilities that patients will not have access to an ideal care.

As per credible sources, the healthcare facilities in the country are stretched thin

MIVI Neuroscience enrolls first patient in EVAQ clinical trial

MIVI Neuroscience enrolls first patient in EVAQ clinical trial

Health

MIVI Neuroscience has recently confirmed that the first patient has been enrolled in the Investigational Device Exemption EVAQ Clinical Study, which has been approved by the U.S. FDA. The enrollment was done in Toulouse, France at Hôpital de Purpan. The trial is a nulti-center, prospective single arm strudy for evaluating the MIVI Q Revascularization System targeting neurointervention in acute ischemic stroke.

The study sites for this EVAQ clinical trial are situated in the U.S. and France. Based on the innovative design of the Q Aspiration Catheter, the Q Revascularization System is able to leverage the larger lumen of the Super 90 8F Guide Catheter for aspiration.

TeraRecon awarded extended patent for diagnostic imaging with AI

TeraRecon awarded extended patent for diagnostic imaging with AI

Health

The new patent would encompass continuous synchronization of AI findings between image integration view and diagnostic report.

Amidst all the apprehensions being held in the medical industry with inclusion of artificial intelligence, TeraRecon has recently announced receiving a landmark patent for diagnostic imaging with AI. Standing tall as the world leader for AI-driven advanced visualization solutions, TeraRecon’s recent strategic move in the market is expected to bring it positive growth opportunities in the years to come.

Now encompassing a bi-directional, interactive AI-informed reporting experience, this n

Picosun unites with researchers & hospitals to drive ALD application

Picosun unites with researchers & hospitals to drive ALD application

Health

Picosun Group, a leading provider of ALD (Automatic Layer Deposition) thin film coating solutions, has reportedly partnered with prominent hospitals and researchers in China.

The deal was inked with an objective to apply its medical ALD technology to ensure safer surgical procedures. To elaborate, the company’s biocompatible ALD coating solutions will be applied to electrotomes (electrosurgical equipment) for enhanced safety, performance, and service life.

Electrotome is the standard equipment that can replace traditional mechanical scalpels in operations. It utilizes high temperature to separate and cut tissue & coagulated bl

PTC Therapeutics initiates the Phase 1 clinical trial of PTC518

PTC Therapeutics initiates the Phase 1 clinical trial of PTC518

Health

PTC Therapeutics has reportedly disclosed the initiation of a Phase 1 clinical trial for the evaluation of PTC518 amongst healthy volunteers. The candidate was recognized from PTC’s splicing platform and is reportedly being created for the treatment of HD (Huntington’s disease).

According to PTC Therapeutics’ CEO, Stuart W. Peltz, the clinical trial’s initiation for the evaluation of PTC518 for the Huntington’s disease initiative is a significant milestone towards the identification of a potential new Huntington’s disease treatment meant for directly addressing the underlying cause of the disease. Peltz has further stated that PTC518 is

Ascentage unveils clinical study results of BCR-ABL inhibitor HQP1351

Ascentage unveils clinical study results of BCR-ABL inhibitor HQP1351

Health

Ascentage Pharma, a renowned clinical-stage biotechnology firm focused on developing new therapies for CHB (chronic hepatitis B), cancers, as well as age-related illnesses, has reportedly announced that outcomes from two Phase II clinical studies of its new BCR-ABL inhibitor, HQP1351, namely olverembatinib, were accepted for an oral presentation at 62nd ASH (American Society of Hematology) Annual Meeting.

Xiaojun Huang, M.D., Peking University People's Hospital, Hematology Department, and Qian Jiang, M.D., who would be presenting the results at the event, are principal investigators of both studies. This would be the 3rd time the company has unvei